MB09 , a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70013 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Monika Tomaszewska-Kiecana und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biokinetica S.A., Józefów, Poland. Hauptthemen laut MEDLINE: Denosumab, Biosimilar Pharmaceuticals, Healthy Volunteers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This was a Phase I, randomized, double‐blinded, three‐arm, single‐dose, parallel study aimed to demonstrate pharmacokinetic (PK) similarity between MB09 (a denosumab biosimilar candidate) and reference denosumab (XGEVA® from European Union [EU‐reference] and United States [US‐reference]) in a healthy male population. The primary PK endpoints included: Area under the serum concentration versus time curve from time 0 to the last quantifiable concentration timepoint (AUC 0–last ); and maximum observed serum concentration ( C max ). Secondary endpoints included: AUC from time 0 extrapolated to infinity (AUC 0–∞ ), time to reach maximum observed concentration, clearance, terminal phase half‐life, pharmacodynamic, safety, and immunogenicity assessments. A total of 255 subjects were randomized (1:1:1) to receive a subcutaneous 35 mg dose of MB09 or reference denosumab. C max was reached after denosumab administration, followed by a decline in the concentration with similar terminal phase half‐live across treatment arms. Systemic exposure of MB09 (AUC 0–last and C max ) was equivalent to the reference denosumab, as the 90% confidence intervals around the geometric least square mean ratios laid within the predefined acceptance limits (80.00%, 125.00%) across all comparisons. Pharmacodynamic parameters, based on the percent of change from baseline in serum C‐terminal telopeptide of Type 1 collagen levels, were similar across the three arms. The treatments were considered safe and generally well tolerated, with 92 treatment‐emergent adverse events reported (most Grade 2 and 3) and similarly distributed. Immunogenicity was low and similarly distributed. These results provide strong evidence that supports the biosimilarity between MB09 and denosumab reference products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biokinetica S.A., Józefów, Poland.
- Medical Department, mAbxience Research S.L.U., Madrid, Spain.
Zitieren
APA
Tomaszewska-Kiecana, M., Carapuça, E., Florez-Igual, A., & Queiruga-Parada, J. (2024). MB09 , a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects. Clinical and Translational Science. https://doi.org/10.1111/cts.70013
Vancouver
Tomaszewska-Kiecana M, Carapuça E, Florez-Igual A, Queiruga-Parada J. MB09 , a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects. Clinical and Translational Science. 2024. doi:10.1111/cts.70013
BibTeX
@article{TomaszewskaKiecana2024,
author = {Tomaszewska-Kiecana, Monika and Carapuça, Elisabete and Florez-Igual, Amalia and Queiruga-Parada, Javier},
title = {MB09 , a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70013}
}
EUVIMED